Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 5.6%

Enliven Therapeutics, Inc. (NASDAQ:ELVN)’s share price was up 5.6% during trading on Tuesday . The stock traded as high as $24.68 and last traded at $24.68. Approximately 21,677 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 269,321 shares. The stock had previously closed at $23.38.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ELVN. Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Mizuho assumed coverage on shares of Enliven Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price objective for the company. Finally, Robert W. Baird started coverage on shares of Enliven Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 target price on the stock.

Enliven Therapeutics Stock Up 4.2 %

The firm has a 50 day moving average price of $22.53 and a 200 day moving average price of $19.02. The stock has a market cap of $1.18 billion, a PE ratio of -12.96 and a beta of 1.11.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Tuesday, May 14th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. Equities analysts forecast that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current year.

Insider Buying and Selling

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,000 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $23.18, for a total transaction of $278,160.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $23.18, for a total value of $278,160.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Anish Patel sold 17,475 shares of the stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $25.07, for a total transaction of $438,098.25. Following the sale, the chief operating officer now directly owns 376,552 shares of the company’s stock, valued at $9,440,158.64. The disclosure for this sale can be found here. Insiders sold 1,142,148 shares of company stock valued at $25,390,954 over the last 90 days. Corporate insiders own 29.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AJOVista LLC purchased a new stake in shares of Enliven Therapeutics during the fourth quarter worth about $28,000. China Universal Asset Management Co. Ltd. acquired a new position in Enliven Therapeutics during the 4th quarter valued at approximately $66,000. EntryPoint Capital LLC purchased a new position in shares of Enliven Therapeutics in the first quarter worth $167,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Enliven Therapeutics by 9.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after buying an additional 1,029 shares during the period. Finally, SG Americas Securities LLC grew its holdings in shares of Enliven Therapeutics by 17.8% during the fourth quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after buying an additional 2,041 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.